VEVYE
Peakcyclosporine ophthalmic solution
NDAOPHTHALMICSOLUTION
Approved
May 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
VEVYE (cyclosporine ophthalmic solution) is calcineurin inhibitors [moa]. First approved in 2023.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEVYE is a calcineurin inhibitor ophthalmic solution approved in May 2023 for topical ocular use. It works by suppressing local immune responses in the eye through calcineurin inhibition. The drug targets patients with inflammatory ocular conditions requiring immunosuppression.
Peak15.4 years to LOE
Early-stage peak product with strong patent protection and growing market penetration; expanding commercial infrastructure and team building underway.
Mechanism of Action
Calcineurin Inhibitors
Pharmacologic Class:
Calcineurin Inhibitor Immunosuppressant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VEVYE represents a rare opportunity to build a specialty ophthalmic franchise from launch through peak with significant patent protection extending 15+ years. Career growth potential is strong for professionals willing to develop expertise in niche immunology and ophthalmic markets.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.